BlossomHill Therapeutics closed at $12.42 on Nov 2, down 9.67%, within 0.0% of its lowest close since Sep 11. Volume of 140.8K shares was 0.94× its 20-day average (close to normal).
Split-adjusted performance: -36.9% over one month.
Short interest was 485.0K shares at the Oct 15 settlement, up 2.4% from the prior report (2.4% of float, 2.9 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.1%, revenue growth +6.4%, net margin −36.2%, P/E 15.8×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BLSMBlossomHill Therapeutics | $12.42 | −9.67% | — | — | — | — | $394.8M | |
| ALTAltimmune | $2.02 | −0.98% | −33.1% | −100.0% | — | — | $392.9M | Compare |
| AVTXAvalo Therapeutics | $7.32 | +2.09% | −46.9% | — | — | — | $392.6M | Compare |
| ASMBAssembly Biosciences | $19.51 | −3.08% | −29.9% | +38.9% | −28.8% | — | $397.2M | Compare |
| RLMDRelmada Therapeutics | $3.84 | +7.26% | −48.2% | — | — | — | $409.6M | Compare |
| TLRYTilray Brands | $2.55 | +0.79% | −56.8% | +22.7% | −16.8% | — | $376.9M | Compare |
| MPLTMapLight Therapeutics | $6.78 | −10.55% | −76.3% | — | — | — | $376.8M | Compare |
| RZLTRezolute, Inc. Common Stock (NV) | $3.88 | −1.77% | +17.6% | — | — | — | $375.3M | Compare |
| CRMDCorMedix | $5.39 | −5.36% | −31.8% | +156.5% | 25.5% | 2.2 | $420.1M | Compare |
No recent articles focused on BlossomHill Therapeutics.
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
